ArticleCancer medicine2026
Immune-Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is an aggressive type of skin cancer. Immune checkpoint inhibitors (ICIs): pembrolizumab, ipilimumab and/or nivolumab are recommended for the treatment of metastatic melanoma. ICIs enhance the immune response by blocking PD-1 and/or CTLA-4, improving remission and overall survival (OS). However, ICIs can cause immune-related adverse events (irAEs) such as colitis and dermatitis. Recent studies have demonstrated association between irAEs and improved tumour regression. This study aimed to evaluate the relationship between OS and stopping ICIs therapy due to immunological toxicity in metastatic melanoma patients. This study was approved by The University Hospitals Sussex NHS Foundation Trust (UHSussex) (reference 1963) and the University of Brighton (reference 2024-12,878-Shamsaldeen). Data collected from files of patients diagnosed with metastatic melanoma treated with ICIs at UHSussex between October 2011 to December 2022. In a total of 344 metastatic melanoma patients, the OS was 41.3%. There were 184 patients (53.5%) experienced irAEs. Among 202 patients who died by the cut-off point, there were 115 (56.9%) patients who did not experience irAE, while 68.3% of the 142 patients who were alive experienced irAE revealing overall association (p < 0.001, Pearson's R = 0.249) with logistics regression analysis showed association between irAE and OS (p < 0.001). Kaplan-Meier survival analysis showed significant longer OS (p < 0.001) for patients experienced irAE. Stopping ICIs due to toxicity reported in 83 patients from which 56 patients were alive by the cut-off point (67.5%) revealing overall association (p < 0.001, Pearson's R = 0.171) with logistics regression analysis showed association between stopping ICI due to toxicity and OS (p < 0.001). Kaplan-Meier survival analysis showed significant longer OS (p = 0.027) in patients whom their ICI therapy was stopped due to immune-related toxicity. In conclusion, the positive correlation between irAEs and survival may highlight the potential value of irAEs and irAE-related toxicity as biomarkers for therapeutic efficacy in advanced melanoma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.